Dupilumab for the Treatment of Alopecia Areata in Pediatric Patients with Atopic Dermatitis: A Scoping Review

    July 2024 in “ Pediatric Dermatology ”
    Dea Metko, Shanti Mehta, Cathryn Sibbald
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary This study reports that dupilumab significantly reduced alopecia areata severity in pediatric patients with atopic dermatitis, indicating potential as an effective treatment option, though further research on long-term safety and optimal use is needed. Our plain-language summary of this paper — not a Tressless recommendation.
    This scoping review examines the use of dupilumab, a monoclonal antibody, for treating alopecia areata (AA) in pediatric patients with atopic dermatitis (AD). Involving 31 patients with an average age of 11.4 years, the study found that 77.4% experienced hair regrowth, with a significant mean reduction in SALT score of 42.6, indicating improved scalp hair coverage. Additionally, the severity of AD decreased significantly. While dupilumab shows potential effectiveness, some cases reported new or worsened AA, suggesting other inflammatory pathways might be involved. The review notes limitations such as small sample size and short follow-up, and emphasizes the need for further research, with a clinical trial (NCT05866562) underway to assess efficacy.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results